Safety and Efficacy Study of Bimosiamose Cream to Treat Psoriasis

Phase 2

Completed

• Conditions: Psoriasis
• Interventions: Drug: Bimosiamose Cream; Drug: Placebo Cream

• Registration Number: NCT00823693
• Lead Sponsor: Revotar Biopharmaceuticals AG

Brief Summary

The purpose of this study is to determine whether Bimosiamose Cream is safe and effective in the treatment of plaque type psoriasis.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-01-14
• Study First Submitted QC: 2009-01-15
• Study First Posted: 2009-01-16
• Status Verified: 2009-08
• Last Update Submitted: 2009-08-20
• Last Update Posted: 2009-08-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 107

Inclusion Criteria

• Clinical diagnosis of plaque type psoriasis PASI score of 5-15
• At least 18 years of age
• Written informed consent

Exclusion Criteria

• Active skin infection
• More than 20% Body Surface Area (BSA) affected by psoriasis
• Use of certain anti-psoriasis medication or treatments

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Bimosiamose Cream	Bimosiamose Cream	-
Placebo Cream	Placebo Cream	-

Trial Locations

Locations (1)

Charité Campus Mitte, Klinik für Dermatologie, Venerologie und Allergologie; 🇩🇪 Berlin, Germany